|
|
|
|
||
Re: Stifel on ACAD: Price target $71gain: Oh I think its recent. We don't know if ACAD might consider taking up that indication at a latter date via doing more work since it was so far along? But they have said they aren't pursuing it further currently. The work done does not disappear--it just gets put on a shelf and collects dust. One can argue that ACAD should currently focus on their agency interactions during their current sNDA review process and focus on selling drug for what is approved versus jacking around on why a primary efficacy parameter failed. But after next April? Who knows? Have seen programs tabled and then re-awakened? That analyst analysis was a very interesting read and especially the part about assessing via the ex-FDA person. I can see how LINK thinks one thing and Biotech thinks another. Maybe they are both right? The FDA has "moved the goal posts" on a program mid stream and at the end in the past. We as investors can only go by the results, what occurred along the way, the actions taken along the way, and THE HOPE that assessment perspective has not changed along the way from the deciders! its the stuff that makes playing stocks for FDA decisions a wicked pisser! Our odds are good, but its never over until its over. JMO kutz |
return to message board, top of board |